What Ranferon-12 Treats: Main Uses and Benefits

Ranferon-12, which is relevant in contexts involving heightened systemic burden, is commonly used across conditions presenting with acute episodes of iron deficiency anemia (IDA). This product is considered relevant in conditions characterized by periods of heightened symptoms of IDA, particularly in patients with chronic kidney disease (CKD). This is commonly used in clinical settings that involve acute or unstable symptom patterns.

The therapeutic domain is applied across areas where short-term symptom management is appropriate for symptoms linked to organ-specific functional stress. The medication may assist with managing symptoms that create noticeable physiological strain. It is commonly used to help with symptoms related to physical discomfort and fatigue.

“It assists with maintaining functional stability and supports general well-being during symptomatic phases.”

It is relevant for easing symptoms associated with acute or episodic changes in iron status, and generally helps patients cope more steadily with symptom fluctuations.

Quick Fact: Relevant for Conditions where Symptoms Interfere with Daily Functioning

Regulatory References

1. NIH DailyMed official prescribing information

The eligibility for using Ranferon-12 is strictly defined by regulatory documents, focusing on absolute exclusions and populations requiring conditional use.

Contraindicated Populations (Must Not Use)

Eligibility-Related Restrictions

These restrictions ensure safe usage by excluding individuals at high risk for iron toxicity or those with underlying conditions that could be masked or worsened by the medicine's components.

Interactions with other medicines and products

The interaction profile for Ranferon-12, a fixed-dose combination containing Iron, Folic Acid, and Cyanocobalamin ( Vitamin B12), is largely structured by pharmacokinetic interactions resulting in modified exposure.

Formal Restrictions and Contraindicated Combinations

Co-administration with Dimercaprol is strictly prohibited due to the risk of toxic complex formation. The regulatory profile also lists a prohibition on co-administering this oral product with Parenteral Iron due to the risk of Iron overload. Folic Acid, one component, may mask the hematological signs of undiagnosed Pernicious Anemia.

Documented Exposure-Modifying Interactions

Many interactions are driven by the Iron component's tendency for chelation and pH-dependent absorption. These interactions generally result in reduced bioavailability for one or both agents.

Certain foods and beverages, including tea, coffee, and milk, are documented to reduce the absorption of Iron and require separation from administration. Similarly, heavy alcohol intake may impair Vitamin B12 absorption.

Ranferon-12 functions through a multi-modal mechanism regulating iron homeostasis and facilitating hemoglobin synthesis. The ferric iron (Fe^3+) component initially undergoes reduction by the enzyme duodenal cytochrome b (Dcytb) into its ferrous (Fe^2+) form. This conversion enhances iron's capacity for uptake into enterocytes via the membrane transporter divalent metal transporter 1 (DMT1), thereby optimizing intestinal absorption. Concurrently, cyanocobalamin (Vitamin B12) acts as an essential co-factor for the enzyme methionine synthase, which catalyzes the re-methylation of homocysteine. This pathway integrates necessary co-factor activity critical for cellular metabolism. Furthermore, folic acid acts as a substrate in the purine and pyrimidine synthesis pathways, which is essential for DNA synthesis and subsequent proper erythrocyte maturation. The aggregate effect of these components modulates metabolic pathways to support the increase of erythrocyte count and circulating hemoglobin levels.

Administration Scope

Ranferon-12 is prescribed as an oral medication, available as a tablet or capsule, and is intended to be swallowed whole with a full glass of water. The fixed-dose combination structure dictates administration through this single, designated route. The tablet must generally not be crushed or chewed.

Dosing and Frequency

The official dosing pattern is determined by the required clinical goal, and all dosages relate to the Elemental Iron content. For the active correction of a deficiency, a therapeutic regimen is typically used, where the dose may total 100 mg to 200 mg daily, administered in divided doses. Conversely, for long-term support or prophylaxis, the prescribed maintenance dose is commonly 60 mg to 65 mg elemental iron equivalent, taken once daily. Standard adult dosing generally applies to older adults, while the tablet form is commonly reserved for patients 12 years of age and older.

Contextual Timing and Duration

To optimize the uptake of the iron component, the label recommends administration on an empty stomach, generally one hour before or two hours after a meal. However, if this timing causes gastrointestinal intolerance, the dose may be taken with food. A key procedural condition is the separation of Ranferon-12 from other substances, such as antacids or calcium supplements, by at least two hours to prevent interference with iron absorption. The course of therapeutic use is often planned for a duration of three to six months and is typically continued after blood parameters normalize to ensure the complete replenishment of the body’s nutrient stores.

Ranferon-12: Recent Clinical Evidence

Clinical Efficacy and Hematological Outcomes

Recent research on Ranferon-12, a combination product containing ferrous fumarate and ferric ammonium citrate (iron salts), Folic Acid, and Cyanocobalamin (Vitamin B12), has focused on its effect on iron status and red blood cell recovery.

A study examining its use in healthy adult blood donors investigated its impact following blood donation. The efficacy results from this trial aligned with prespecified criteria, showing that daily administration over a six-week period was associated with changes in hematological parameters.

Key measured outcomes in the study included an increase in Hemoglobin (Hb) levels, Red Blood Cell (RBC) indices (such as Mean Cell Volume or MCV), and markers of iron stores like serum ferritin. The study reported a moderate significant positive correlation between the product's use and changes in these measured values.

Safety Profile and Ongoing Research

Studies examining the safety profile of iron supplementation, including regimens similar to Ranferon-12 syrup, have highlighted potential gastrointestinal effects. For example, some protocols have investigated the possibility of increased fecal occult blood losses, which may suggest gut mucosal irritation, an effect commonly associated with oral iron therapy.

Research protocols specified that doses were administered in a manner intended to optimize absorption. However, the presence of various iron salts and co-factors is studied to see how it affects the overall tolerability of the regimen. Currently, research continues to evaluate the development of regimens that minimize gastrointestinal side effects while maintaining efficacy.

Key Studies & References

1. Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota
2. Comparison of Efficacy and Safety Profile of Oral Iron Formulations in Patients with Iron Deficiency Anemia

Common questions about Ranferon-12 (FAQ)

Q: What is Ranferon-12 and how is it used?

Ranferon-12 is a medicine used to treat and prevent nutritional anemia, which is a type of anemia caused by a deficiency of certain nutrients. It is a hematinic preparation, meaning it helps in the formation of blood cells. It is typically prescribed when a person does not get enough of these essential components, such as iron, vitamin B12, and folic acid, from their regular diet.

Q: What are the active ingredients in Ranferon-12?

The primary active ingredients are:

• Ferrous Fumarate: This is an iron salt, which is essential for making hemoglobin, the part of red blood cells that carries oxygen.
• Vitamin B12 (Cyanocobalamin): This vitamin is crucial for the formation of healthy red blood cells and nerve function.
• Folic Acid (Vitamin B9): This is another B vitamin necessary for cell division and the production of red blood cells.

Q: How should I take Ranferon-12?

It is typically taken orally as a capsule or tablet, usually once a day with a meal or as directed by a healthcare professional. Taking it with food can help reduce stomach upset. Do not chew or crush capsules; swallow them whole with a glass of water. Follow the exact instructions provided by your doctor or pharmacist regarding the frequency and duration of treatment.

Q: What if I miss a dose of Ranferon-12?

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed one. If you are unsure, consult your healthcare provider.

Q: Are there common side effects associated with Ranferon-12?

Common side effects, particularly due to the iron component, may include:

• Gastrointestinal upset, such as nausea, stomach pain, or cramps.
• Constipation or, less commonly, diarrhea.
• Darkening of the stools, which is a normal and harmless effect of iron supplements.

These side effects are usually mild and may lessen as your body adjusts to the medication. If side effects are severe or persistent, contact your healthcare provider.

Q: Who should not take Ranferon-12?

Ranferon-12 is not suitable for everyone. You should avoid this medicine if you have:

• A known allergy to any of its components (Ferrous Fumarate, Vitamin B12, or Folic Acid).
• Conditions like hemochromatosis (a condition causing too much iron to build up in the body) or other iron overload disorders.
• Certain types of non-nutritional anemia, such as aplastic anemia or pernicious anemia not related to B12 deficiency.

Always inform your doctor of your full medical history before starting this treatment.

Ranferon-12, a haematinic fixed-dose combination, must be stored according to specific regulatory requirements to maintain its chemical stability until the expiration date.

Official Storage Conditions

Disposal Instructions

Unused or expired Ranferon-12 must be disposed of in accordance with local regulatory requirements. The product should not be discarded into household wastewater (flushed down the toilet or poured down a sink) unless specific governmental instructions for this product state otherwise.